Topic resource collection
Approved comparison material connected to this topic.
1378 resourcesRead both sides
Primary Mechanism NNMT enzyme inhibition → increased NAD+ → mitochondrial fat oxidation Triple monoamine reuptake inhibition (serotonin, norepinephrine, dopamine) → appetite suppression 5-Amino-1MQ targets cellular metabolism; te…
Mechanism of Action Direct dopamine/norepinephrine reuptake inhibition or release stimulation Receptor modulation, neurotrophin upregulation, synaptogenesis promotion Peptides avoid neurotransmitter flooding. Fewer acute cardiova…
Storage (Lyophilised) −20°C freezer, sealed desiccant bag Room temperature shelf, ambient humidity 35–80% bioactivity loss within 72 hours depending on ambient temperature Non-negotiable cold storage—temperature abuse is the sing…
Thymalin Thymic immunomodulation. Reduces IL-6, TNF-alpha, cortisol Peripheral cytokine suppression → reduced microglial activation 6–8 weeks (two cycles) 1–2mg subcutaneous, 5 consecutive days, 25-day rest Best for immune-driven…
A 2023 systematic review published in Frontiers in Pharmacology found that prescription stimulant-based smart drugs (modafinil, methylphenidate, amphetamines) produce measurable cognitive enhancement in healthy adults. But at the…
Thymalin Thymic peptide. Normalizes T-regulatory cell ratios, reduces dermal inflammation (IL-6, TNF-alpha suppression) 5–10mg every 3–4 days Subcutaneous injection Yes. Bacteriostatic water 28 days at 2–8°C MK-677 Ghrelin recept…
Thymalin Thymic epithelial regeneration, T-regulatory cell production Reduces systemic inflammation (inflammaging), stabilizes atherosclerotic plaques 5–10mg subcutaneous, 2x weekly IL-6 reduction 18–22%, Treg count increase 28–3…
Let's be direct: the term 'safer' is doing heavy lifting here, and it's masking two completely different risk profiles. Prescription smart drugs carry known, quantified risks. Cardiovascular strain, dependency, sleep disruption. …
BPC-157 VEGF upregulation, angiogenesis, FAK-paxillin signaling Tendon tears, ligament sprains, chronic tendinopathies 200–400 mcg/day subcutaneous Strong preclinical (rodent models), no human RCTs Gold standard for tendon/ligame…
BPC-157 VEGF upregulation, angiogenesis acceleration Within 6 hours post-surgery 250–500mcg twice daily ~4 hours Best for mucosal repair and vascular regeneration. Critical in the first 48 hours TB-500 Actin polymerization, kerat…
Selecting the right Glow Stack syringes needles supplies depends on protocol volume, peptide characteristics, and whether reconstitution or administration is the primary use case. The table below maps equipment specifications to …
Cartilage homeostasis research Chondrocyte gene expression modulation via nuclear chromatin binding 100–500 μg/day subcutaneous, 30–60 day cycles Gene expression changes detectable at 48–72 hours; matrix synthesis effects measura…
Growth Hormone Secretagogues Ipamorelin, CJC-1295, MK-677 200–500 mcg per administration 28 days refrigerated in bacteriostatic water GH axis modulation, anabolic pathway studies Best for facilities with consistent refrigeration—…
The table below summarizes the three major developments in peptide news November 2026, including regulatory changes, metabolic peptide advances, and neuroprotective breakthroughs. FDA 503B Guidance (Nov 14) Formalized quality sta…
The following table compares the leading peptide categories by primary research application, typical concentration ranges used in published studies, and key mechanistic distinctions that drive laboratory selection criteria. GLP-1…
Research published by the Journal of Pharmaceutical Sciences found that subcutaneous peptide administration produces peak plasma concentrations 30–60 minutes later than intramuscular injection. But maintains therapeutic levels fo…
The table below compares the two categories across five critical research criteria: mechanism of action, bioavailability, administration route, onset time, and regulatory classification. Mechanism of Action Direct receptor agonis…
The evolution of hexarelin research produced multiple analogs designed to separate GHS-R activity from CD36 binding. This table summarizes the key compounds and their receptor profiles as established in peer-reviewed studies betw…
Phase 1 (Weeks 1–2) BPC-157 250mcg/day 1.75mg BPC-157 VEGF upregulation, TNF-alpha suppression, angiogenesis initiation CRP reduction 25–40%, IL-6 reduction 15–30% Establishes anti-inflammatory baseline. Skipping this phase remov…
Researchers often evaluate kisspeptin alongside other peptides that interact with the HPG axis. The table below compares kisspeptin-10, gonadorelin (GnRH), and hCG based on mechanism, receptor target, half-life, and experimental …